OBIO - NASDAQ
Orchestra BioMed Holdings, Inc.
$3.86
-0.52%Orchestra BioMed Holdings, Inc. operates as a biomedical innovation company. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension; and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease. Its products also comprise FreeHold retractors that are minimally invasive surgical device solutions. The company has a strategic collaboration with Medtronic for the development and commercialization of BackBeat CNT for the treatment of hypertension in pacemaker-indicated patients; and a strategic partnership with Terumo Corporation for the development and commercialization of Virtue SAB for the treatment of artery disease. Orchestra BioMed Holdings, Inc. is based in New Hope, Pennsylvania.
At a Glance
Live Snapshotobio
Additional Paid-In Capital
Last Annual Value
416.08M
3-Year CAGR
18%
5-Year CAGR
34%
10-Year CAGR
16%
Orchestra BioMed Holdings, Inc. Competitors Analysis of Additional Paid-In Capital
| Company | Additional Paid-In Capital | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
Orchestra BioMed Holdings, Inc. NASDAQ:OBIO | 416.08M | 9.5% | 34.4% | N/A | |
 Enanta Pharmaceuticals, Inc. NASDAQ:ENTA | 469.77M | 3.4% | 6.0% | 6.9% | |
 Avalo Therapeutics, Inc. NASDAQ:AVTX | 531.49M | 15.8% | 13.3% | 22.4% | |
 Invivyd, Inc. NASDAQ:IVVD | 1.20B | 9.6% | 7.1% | N/A | |
 Prelude Therapeutics Incorporated NASDAQ:PRLD | 751.68M | 2.7% | 8.2% | N/A | |
 Caribou Biosciences, Inc. NASDAQ:CRBU | 718.58M | 2.5% | 8.1% | N/A | |
 Codexis, Inc. NASDAQ:CDXS | 657.29M | 4.0% | 3.6% | 7.8% | |
 Corbus Pharmaceuticals Holdings, Inc. NASDAQ:CRBP | 702.98M | 17.8% | 10.9% | 32.5% | |
 Neonc Technologies Holdings, Inc. NASDAQ:NTHI | 97.95M | 58.2% | 40.2% | N/A | |
 OmniAb, Inc. NASDAQ:OABI | 433.18M | 7.0% | N/A | N/A | |
 Cassava Sciences, Inc. NASDAQ:SAVA | 0.00 | N/A | N/A | N/A |
Orchestra BioMed Holdings, Inc. Fair Value Envelope
Related Guides
Continue your OBIO research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.